Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Michael Friedman named "lead deputy" commissioner.

This article was originally published in The Tan Sheet

Executive Summary

FDA DEPUTY COMMISSIONER FRIEDMAN WILL BE DE FACTO ACTING COMMISSIONER, assuming the duties of commissioner when David Kessler departs the agency in late February. Deputy Commissioner for Operations Michael Friedman, MD, will not be given the formal title of acting commissioner. Instead, he has been named "lead deputy commissioner, in which capacity he will perform the duties of commissioner when I depart," Kessler told FDA staff in a Jan. 30 memo. "This is necessary because the current FDA organizational structure provides no line of succession when the position of commissioner...becomes vacant," Kessler explained.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel